The FDA approved a myeloma combination therapy showing an 83% relative reduction in the risk of disease progression or death and over 50% reduction in mortality risk — one of the strongest efficacy signals in recent hematologic oncology.

The approval is based on the MajesTEC-3 trial, a phase III study of 587 patients with relapsed or refractory multiple myeloma published in the New England Journal of Medicine. The combination was approved in just 55 days after filing under the FDA's National Priority Voucher program, reflecting the strength of the clinical data.

The therapy carries a Boxed Warning for cytokine release syndrome and neurologic toxicity — serious but manageable side effects that require monitoring infrastructure. Janssen Biotech secured the approval through an accelerated pathway designed to fast-track treatments with transformative efficacy.

For oncology practices and health systems, the approval creates both clinical opportunity and operational complexity. The monitoring requirements for cytokine release syndrome mean community oncology practices may need to invest in infusion center capabilities or refer patients to academic centers. Payer negotiations on pricing will be closely watched given the survival benefit magnitude.

Read the full article →